Dr. Martin Barr

• Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne., VEGF is an autocrine growth factor, signalling through Neuropilin-1 in non-small cell lung cancer, Molecular Cancer, In Press, (In Press), 2015Journal Article, 2015
• Barr MP, O'Byrne KJ, Al-Sarraf N, Gray SG., VEGF-mediated cell survival in NSCLC: Implications for epigenetic targeting of VEGF receptors as a therapeutic approach, Epigenomics, 2015Journal Article, 2015
• MacDonagh L, Gray SG, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, The emerging role of microRNAs in resistance to lung cancer treatments, Cancer Treatment Reviews, 41, (2), 2015, p160 - 169Review Article, 2015, URL
• Dowling P, Pollard D, Larkin AM, Michael H, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarity M, O'Brien E, Morgan R, Clynes M. , Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer , Molecular Biosystems, 2014Journal Article, 2014, URL
• O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP., The role of DNA repair pathways in cisplatin resistant lung cancer, Cancer Treatment Reviews, 40, (10), 2014, p1161 - 1170Review Article, 2014, URL
• Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn S, O'Byrne K, Gately K., Strategic targeting of the PI3K-NFkB axis in cisplatin resistant NSCLC, Cancer Biology & Therapy, 15, (10), 2014, p1367 - 1377Journal Article, 2014, URL
• Barr MP, MacDonagh L, O'Byrne KJ., Markers of response to platinum-based chemotherapy in lung cancer, Lung Cancer Management, 2, (3), 2013, p1 - 13Review Article, 2013
• Gao Y, Baird AM, Barr MP, Gately K, O'Byrne KJ, Gray SG., Epigenetic therapy for cisplatin resistance in non-small cell lung cancer: the way forward?, Lung Cancer Management, 2, (1), 2013, p1 - 4Review Article, 2013
• O'Flathery JD, Barr M, Fennell D, Richard D, Reynolds J, O'Leary J, O'Byrne K., The Cancer Stem-Cell Hypothesis: Its Emerging Role in Lung Cancer Biology and its Relevance for Future Therapy, Journal of Thoracic Oncology, 7, (12), 2012, p1880 - 1890Review Article, 2012, URL
• Molecular Mechanisms of Cisplatin Resistance in Lung Cancer. in, editor(s)Gately, KA , Lung Cancer: A Comprehensive Overview. , New York, Nova Science Publishers, 2013, pp171 - 190, [Martin P Barr]Book Chapter, 2013
• MacDonagh,Lauren , Gray,Steven George, Finn,Stephen P. , Cuffe,Sinead D. , O'Byrne,Kenneth John, Barr,Martin P. , The emerging role of microRNAs in resistance to lung cancer treatments, Cancer Treatment Reviews, 41, (2), 2015, p160-169Journal Article, 2015, DOI
• Leon, G., MacDonagh, L., Finn, S.P., Cuffe, S., Barr, M.P., Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways, Pharmacology and Therapeutics, 158, 2016, p71 - 90Journal Article, 2016
• MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Lung cancer stem cells: The root of resistance., Cancer letters, 372, (2), 2016, p147-56Journal Article, 2016, DOI
• Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International journal of oncology, 48, (3), 2016, p1290-6Journal Article, 2016, DOI
• MacDonagh Lauren, Gallagher Michael F, Ffrench Brendan, Gasch Claudia, Breen Eamon, Gray Steven G, Nicholson Siobhan, Leonard Niamh, Ryan Ronan, Young Vincent, O'Leary John J, Cuffe Sinead, Finn Stephen P, O'Byrne Kenneth J, Barr Martin P, Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC , Oncotarget , 8 , (42 ), 2017, p72544 - 72563Journal Article, 2017, DOI , URL
• Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K., Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines., Scientific Reports, 8, (1), 2018, p1652-Journal Article, 2018, DOI , TARA - Full Text
• Knopf KM, Murphy BL, MacMillan SN, Baskin JM, Barr MP, Boros E, Wilson JJ., In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes., Journal of the American Chemistry Society, 139, (40), 2017, p14302 - 14314Journal Article, 2017
• Yan Y, Jiang K, Liu P, Zhang X, Dong X, Gao J, Liu Q, Barr MP, Zhang Q, Hou X, Meng S, Gong P., Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways., Scientific Reports, 6, 2016, p37052-Journal Article, 2016
• Hu L, Sun S, Wang T, Li Y, Jiang K, Lin G, Ma Y, Barr MP, Song F, Zhang G, Meng S., Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy., American Journal of Cancer Research, 5, (12), 2015, p3612 - 3623Journal Article, 2015
• Barr MP, O'Byrne KJ, Al-Sarraf N, Gray SG., VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach., Epigenomics, 7, (6), 2015, p897 - 910Journal Article, 2015
• Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ., Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer., Molecular Cancer, 14, 2015, p45-Journal Article, 2015
• Dowling P, Pollard D, Larkin A, Henry M, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarty M, O'Brien E, Morgan R, Clynes M., Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer., Molecular Biosystems, 11, (3), 2015, p743 - 752Journal Article, 2015
• Barr MP, Bouchier-Hayes DJ, Harmey JJ., Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia., International Journal of Oncology, 32, (1), 2008, p41 - 48Journal Article, 2008
• Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, Bouchier-Hayes DJ, Harmey JH., A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells., British Journal of Cancer, 92, (2), 2005, p328 - 333Journal Article, 2005
• Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ., Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells., British Journal of Cancer, 85, (2), 2001, p273 - 278Journal Article, 2001
• Circu M, Cardelli J, Barr M, O'Byrne K, Mills G, El-Osta H., Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells., PLoS One, 12, (9), 2017, pe0184922-Journal Article, 2017, DOI , TARA - Full Text
• MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin., Translational Oncology, 14, (4), 2021, p101025-Journal Article, 2021
• MacDonagh, L. and Gray, S.G. and Breen, E. and Cuffe, S. and Finn, S.P. and O'Byrne, K.J. and Barr, M.P., BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC, Cancer Letters, 428, 2018, p117-126Journal Article, 2018, DOI , URL
• Ryan, S.-L. and Beard, S. and Barr, M.P. and Umezawa, K. and Heavey, S. and Godwin, P. and Gray, S.G. and Cormican, D. and Finn, S.P. and Gately, K.A. and Davies, A.M. and Thompson, E.W. and Richard, D.J. and O'Byrne, K.J. and Adams, M.N. and Baird, A.-M., Targeting NF-KB-mediated inflammatory pathways in cisplatin-resistant NSCLC, Lung Cancer, 135, 2019, p217-227Journal Article, 2019, DOI , URL
• Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG., When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?, Frontiers in endocrinology, 10, 2019, p89Journal Article, 2019, DOI
• Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, Yao G, Wang Y, Chen H, Cheng W, Barr MP, Liu Q, Zhang G, Ding C, Meng S., Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells., BMC Cancer, 18, (1), 2018, p746Journal Article, 2018, DOI
• Liu M, Jiang K, Lin G, Liu P, Yan Y, Ye T, Yao G, Barr MP, Liang D, Wang Y, Gong P, Meng S, Piao H., Ajuba inhibits hepatocellular carcinoma cell growth via targeting of ß-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation., Journal of experimental & clinical cancer research : CR, 37, (1), 2018, p165Journal Article, 2018, DOI
• Ye T, Jiang K, Wei L, Barr MP, Xu Q, Zhang G, Ding C, Meng S, Piao H., Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells., American journal of cancer research, 8, (8), 2018, p1514-1527Journal Article, 2018, DOI
• Martin P. Barr, Patient-oriented Biobanking for Cancer Research, Cancer Studies & Therapeutics, 4, (3), 2019, p1 - 2Journal Article, 2019
• Flynn L*, Barr MP*, Baird AM*, Smyth P, Casey OM, Blackshields G, Greene J, Pennington SR, Hams E, Fallon PG, O'Leary JJ, Sheils O, Finn SP. , Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness., Scientific Reports, 10, (1), 2020, p11329-Journal Article, 2020
• Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium., Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort., Modern Pathology, 33, (5), 2020, p792 - 801Journal Article, 2020
• Hu L, Shen D, Liang D, Shi J, Song C, Jiang K, Menglin Ren, Du S, Cheng W, Ma J, Li S, Bi X, Barr MP, Fang Z, Xu Q, Li W, Piao H, Meng S., Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth., Cancer Letters, 493, 2020, p156 - 166Journal Article, 2020
• MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Gray SG, Reidy M, Nicholson S, Leonard N, Ryan R, Young V, O'Leary JJ, Cuffe S, Finn SP, O'Byrne KJ, Barr MP., MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer., Translational lung cancer research, 10, (4), 2021, p1773-1791Journal Article, 2021, DOI
• Field JK, Liloglou T, Niaz A, Bryan J, Gosney JR, Giles T, Brambilla C, Brambilla E, Vesin A, Timsit JF, Hainaut P, Martinet Y, Vignaud JM, Thunnissen FB, Prinsen C, Snijders PJ, Smit EF, Sozzi G, Roz L, Risch A, Becker HD, Elborn JS, Magee ND, Montuenga LM, Pajares MJ, Lozano MD, O'Byrne KJ, Harrison DJ, Niklinski J, Cassidy A, EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration., The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, 34, (6), 2009, p1477-86Journal Article, 2009, DOI
• O'Byrne KJ, Barr MP, Gray SG., The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer, Cancers, 3, (1), 2011, p1426 - 1453Journal Article, 2011, DOI , URL , TARA - Full Text
• KJ O'Byrne, The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer, Cancers , 3, (1), 2011, p1426-1453Journal Article, 2011, DOI , URL , TARA - Full Text
• Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ., Generation and characterisation of Cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature., PloS one, 8, (1), 2013, pe54193Journal Article, 2013, DOI , URL , TARA - Full Text
• Barr M, Souan L, MacGabhann P, Muller J, Al-Ashhab M, Jasser M, Hamza K, Al-Hassoon S, Kuhn U, Infante D, Lawlor D, Kately K, Amireh E, O'Byrne K, Sughayer MA., The establishment of an ISO compliant cancer biobank for Jordan and its neighboring countries through knowledge transfer and training., Biopreservation and biobanking, 12, (1), 2014, p3-12Journal Article, 2014, DOI , TARA - Full Text
• Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K., Targeting nuclear factor-kappa B to overcome resistance to chemotherapy., Frontiers in oncology, 3, 2013, p120Journal Article, 2013, DOI , TARA - Full Text

• Martin P. Barr, Lung Cancer Screening: is Ireland ready?, 7, 2, Medical Independent, Medical Independent, July, 2021, p20 - 22Report

Cancer,

• Member of the Health Research Board-Clinical Research Coordination Ireland (HRB-CRCI).
• Member of the Irish Association for Cancer Research (IACR).
• Irish Lung Cancer Alliance (ILCA).
• Member of the Irish Thoracic Society (ITS).
• Member of the International Association for the Study of Lung Cancer (IASLC).
• Fellow of the Institute of Biomedical Science UK (IBMS).
• Member of Council of the Irish Association of Clinical Scientists (IACS).
• Member of Clinical Trials Ireland (CTI).
• Member (Associate) of the European Society for Medical Oncology (ESMO).
• Member of the National Standards Authority of Ireland (NSAI)- National Mirror Committee for Biobanking Standards in Ireland (ISO 20387).
• Member of the Academy of Clinical Science & Laboratory Medicine (ACSLM).
• Chartered Scientist (Science Council, UK).
• Member & Ambassador of the European Association for Cancer Research (EACR).
• Member of the European Respiratory Society (ERS).
• Member of the Irish Platform for Patients' Organisations, Science and Industry (IPPOSI).